2 results
Approved WMOCompleted
Primary Objective:To determine the efficacy of ponatinib in patients with CML in CP, AP or BP or with Ph+ ALL who either:are resistant or intolerant to either dasatinib or nilotinib,Or:have the T315I mutation.Secondary Objectives:* To further…
Approved WMORecruiting
(1) To examine whether the exposure to BWL yields clinically significant reductions in CRF compared to exposure to dim white light in (non-)Hodgkin survivors. (2) To examine the effect of exposure to BWL compared to DWL on sleep quality and…